slide1
Download
Skip this Video
Download Presentation
Background

Loading in 2 Seconds...

play fullscreen
1 / 22

Background - PowerPoint PPT Presentation


  • 112 Views
  • Uploaded on

Adherence to HAART in French HIV-infected injecting drug users The contribution of buprenorphine drug maintenance treatment (Contact: Bruno SPIRE [email protected]) B Spire, C Raynaud, MP Carrieri, JA Gastaut, JP Cassuto, J Moreau, JP Moatti and the MANIF 2000 study group. Background.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Background' - ping


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
Adherence to HAART in French HIV-infected injecting drug usersThe contribution of buprenorphine drug maintenance treatment(Contact: Bruno [email protected])B Spire, C Raynaud, MP Carrieri, JA Gastaut, JP Cassuto, J Moreau, JP Moatti and the MANIF 2000 study group
efficacy of haart
Efficacy of HAART
  • HAART has reduced mortality and morbidity in HIV disease since 1996
    • decrease of opportunistic infections incidence

6 times average reduction in the French Hospitals statistics (DMI2) in 1997 vs 1995

    • decrease of hospitalization days

-53% in the DMI2

  • HAART significantly reduces HIV replication, and therefore prevents disease progression
factors associated with haart efficacy
Factors associated with HAART efficacy
  • Lack of history of antiretroviral treatment

(naive patients)

  • Lower viral load before HAART initiation
  • Higher CD4 levels before HAART initiation
  • Lack of use of Saquinavir as a single PI
  • Adherence to treatment is a MAJOR factor
how is adherence among french idus
How is adherence among French IDUs?
  • In the French context, there is no economic barrier to access to HAART
  • Buprenorphine DMT is widely prescribed in France (57,000 treated individuals in 1998 vs 7700 in Methadone programs)
objectives
Objectives
  • To measure adherence to treatment in HIV patients infected through drug use
  • To identify determinants of adherence in this population
  • To measure the impact of buprenorphine drug maintenance treatment on adherence
slide8
The MANIF 2000 Cohort
  • French prospective cohort of HIV-infected injecting drug users with CD4>300 at enrollment and no opportunistic infection
  • Initiated in July 1995
  • Follow-up every 6 months
  • 467 patients included
methods1
Methods
  • Cross-sectional study : Selection of the patient ’s first visit in the cohort after HAART initiation (164 patients)
  • Medical questionnaires, self-questionnaires and face to face interviews
  • Socio-demographic data, depression scales (CES-D), negative life events scales, drug use history, risk behaviours, alcohol and current drug use, access to DMT, adherence assessment
  • Statistical analyses (uni and mulivariate analyses)
adherence assessment
Adherence assessment

Patients were considered “non-adherent” if

  • they declared in the face-to-face interview that they took less than 80% of the total dose of antiretroviral drug prescribed during the week prior to the visit

or

  • if they recognised in the self-administered questionnaire, that they have not been “ totally adherent ” with HAART during the same period.
adherence rate
Adherence rate
  • 467 patients enrolled in the MANIF 2000 cohort
    • of these, 172 patients were started on HAART at the time of study
    • of the 172 patients, data were available for 164 patients (response rate = 95.3%)
  • At 5.3 month in average after HAART initiation, 65.2% (n=107) of patients were adherent to treatment
  • Non-adherent patients have a higher viral load (p=0.006)
adherence and viral load
Adherence and viral load

Median decrease in viral load titres after initiation of HAART was significantly lower among non-adherent (0.53 log copies/ml) than among adherent patients (1.04 log copies/ml)

(p = 0.025)

N=164

n (%)

Non

Adherent

Adherent

Virological

success

61(57)

23 (40)

Virological

failure

46 (43)

34 (60)

p = 0.04

slide16
Financial

problems

ADHERENCE

Alcohol/

20 U-months

Active IDU

vs DMT

Troubles with

the police

Higher

education

OR

> 80 pills

/week

Sex

NLE/

2 events

Ex IDU

vs DMT

Lack of

social

support

Regular

job

Treatment

naïve

Age/10 y

ADHERENCE

significant factors related to non adherence in multivariate analysis 1
Significant factors related to non-adherence in multivariate analysis (1)
  • Negative life events (NLE)
    • number of NLE 20%/event
    • troubles with the police OR = 4.6 95%CI[1.93-10.80]
    • major financial problems OR = 7.3 95%CI[1.32-74.05]
  • Alcohol consumption 20% / 25 monthly glasses
  • Young age -10%/year
  • Active IDU
significant factors related to non adherence in multivariate analysis 2
Significant factors related to non-adherence in multivariate analysis (2)
  • Young age
  • Alcohol consumption
  • Negative life events (NLE)
  • Active IDU>Ex-Tox>DMT
    • Non adherence was similar among IDU on DMT with or without injecting drug use
    • Physicians tended to perceive ex-IDUs as more likely to be adherent (82.3%) than those on DMT (64.5%) or active IDUs (65.0%) (p<0.05).
limitations
Limitations
  • Selection of a particular subgroup of IDUs?
  • Short-term adherence
  • No possible comparison between Methadone programs and buprenorphine DMT
discussion1
Discussion

Associating Buprenorphine with HAART may increase adherence among opiate -dependent patients

  • DMT could be associated with a better medical care taking into account negative life events
  • Better treatment perception among DMT patients
  • DMT could prevent from forgetting, since withdrawing symptoms could occur if buprenorphine doses are missed
acknowledgements to the manif 2000 study group
C Boirot

AD Bouhnik

MP Carrieri

JP Cassuto

P Dellamonica

P Dujardin

N Escaffre

H Gallais

JA Gastaut

G Lepeu

A Loundou

C Marimoutou

D Mechali

JP Moatti

J Moreau

Y Obadia

C Pradier

D Rey

C Reynaud-Morupt

A Schaeffer

B Spire

C Tamalet

F Trémolières

D Vlahov

Acknowledgements to the Manif 2000 study group
ad